Clorox Co vs Danaher Corporation — how do they compare? Clorox Co trades at $108.39 (market cap $13.02B), while Danaher Corporation trades at $207.03 (market cap $147.18B). The key difference: Danaher Corporation is far larger — about 11.3× Clorox Co's market cap, and Clorox Co pays the higher dividend (4.64%). Which is the better fit depends on your goals.
| CLX | DHR | |
|---|---|---|
Market Cap | $13.02B | $147.18B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $242.05 |
52-Week Low | $86.12 | $161.91 |
Enterprise Value | $18.40B | $169.39B |
Dividend Yield | 4.64% | 0.76% |
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $105.15, down 0.43% today, with a bullish technical signal from moving averages and strong momentum indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.66, though Q4 2025 missed. The company reported fiscal 2025 revenue of $7.10 billion and net income of $810 million, with a high ROE of 285.64% but elevated P/B ratio of 141.28. Dividend increased to $1.25 per share, payable August 28, 2026.
Outlook is mixed: bullish technicals and profitability contrast with analyst caution (10.34% buy ratings) and a consensus price target of $97.50 below current price. Risks include inflation pressures and competitive threats from private labels. Upside hinges on execution of cost-saving initiatives and market share recovery.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Trailing returns across standard periods
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →